Natixis Purchases Shares of 21,064 Insulet Co. (NASDAQ:PODD)

Natixis purchased a new stake in Insulet Co. (NASDAQ:PODD) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 21,064 shares of the medical instruments supplier’s stock, valued at approximately $3,610,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in PODD. Raymond James Financial Services Advisors Inc. lifted its stake in shares of Insulet by 26.0% in the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 4,284 shares of the medical instruments supplier’s stock valued at $930,000 after purchasing an additional 884 shares in the last quarter. Assenagon Asset Management S.A. lifted its stake in shares of Insulet by 119.1% in the 4th quarter. Assenagon Asset Management S.A. now owns 79,375 shares of the medical instruments supplier’s stock valued at $17,223,000 after purchasing an additional 43,147 shares in the last quarter. McGlone Suttner Wealth Management Inc. acquired a new position in shares of Insulet in the 4th quarter valued at about $87,000. Fifth Third Bancorp lifted its stake in shares of Insulet by 8.1% in the 4th quarter. Fifth Third Bancorp now owns 7,234 shares of the medical instruments supplier’s stock valued at $1,570,000 after purchasing an additional 544 shares in the last quarter. Finally, Chicago Capital LLC lifted its stake in shares of Insulet by 30.6% in the 4th quarter. Chicago Capital LLC now owns 105,610 shares of the medical instruments supplier’s stock valued at $22,915,000 after purchasing an additional 24,747 shares in the last quarter.

Insider Activity

In related news, SVP Mark N. Field sold 2,131 shares of the company’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $190.43, for a total transaction of $405,806.33. Following the completion of the transaction, the senior vice president now directly owns 14,375 shares in the company, valued at approximately $2,737,431.25. The sale was disclosed in a document filed with the SEC, which is available through this link. In related news, SVP Mark N. Field sold 2,131 shares of the company’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $190.43, for a total transaction of $405,806.33. Following the completion of the transaction, the senior vice president now directly owns 14,375 shares in the company, valued at approximately $2,737,431.25. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Timothy J. Scannell sold 7,000 shares of the company’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $190.51, for a total value of $1,333,570.00. Following the transaction, the director now owns 35,586 shares of the company’s stock, valued at $6,779,488.86. The disclosure for this sale can be found here. In the last ninety days, insiders sold 13,931 shares of company stock worth $2,636,286. 0.47% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $234.00 price objective on shares of Insulet in a research note on Tuesday. Barclays reduced their price objective on Insulet from $213.00 to $200.00 and set an “equal weight” rating on the stock in a research note on Monday, May 13th. Wolfe Research raised Insulet from a “peer perform” rating to an “outperform” rating and set a $200.00 price objective on the stock in a research note on Tuesday, May 7th. OTR Global reissued a “mixed” rating on shares of Insulet in a research report on Monday, June 10th. Finally, Redburn Atlantic assumed coverage on Insulet in a research report on Thursday, May 30th. They set a “buy” rating and a $235.00 price target on the stock. Four research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat.com, Insulet currently has an average rating of “Moderate Buy” and a consensus target price of $239.18.

Insulet Price Performance

Shares of NASDAQ PODD opened at $187.26 on Friday. Insulet Co. has a twelve month low of $125.82 and a twelve month high of $283.00. The company has a current ratio of 3.74, a quick ratio of 2.75 and a debt-to-equity ratio of 1.72. The company has a market capitalization of $13.12 billion, a price-to-earnings ratio of 57.84, a price-to-earnings-growth ratio of 3.50 and a beta of 1.16. The business has a 50 day simple moving average of $193.12 and a 200-day simple moving average of $184.80.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $0.73 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.34. Insulet had a return on equity of 34.06% and a net margin of 13.14%. The business had revenue of $441.70 million during the quarter, compared to the consensus estimate of $424.05 million. During the same period in the previous year, the business earned $0.23 EPS. The business’s quarterly revenue was up 23.3% on a year-over-year basis. As a group, equities research analysts expect that Insulet Co. will post 3.11 earnings per share for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.